Research programme: RSV vaccine - Uvax Bio
Latest Information Update: 11 Mar 2024
Price :
$50 *
At a glance
- Originator Uvax Bio
- Class Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Respiratory syncytial virus infections
Most Recent Events
- 20 Dec 2023 Uvax Bio holds the exclusive worldwide rights to the 1c-SApNP® platform and an expanding portfolio of 12 patented preclinical vaccine candidates, prior to December 2023 (UVax Bio pipeline, December 2023)
- 20 Dec 2023 Early research in Respiratory syncytial virus infections(Prevention) in USA (Parenteral), prior to December 2023 (Uvaxbio pipeline, December 2023)